Clinical Research Details Clinical Research Open-Label, Phase 2, Multiple Dose Study to Evaluate the Pharmacodynamic Effects, Safety, and Tolerability of Patiromer in Children under 12 Years of Age with Hyperkalaemia Study Description A Study to Evaluate the Pharmacodynamic Effects, Safety, and Tolerability of Patiromer in Children under 12 Years of Age with Hyperkalaemia. Clinical data shown the benefits of patiromer in adult patients with hyperkalemia. Safety and effectiveness of patiromer has not been evaluated in pediatric patients <6 years of age. This is the first study to explore the use of patiromer in children from birth to <6 years of age. Inclusion/Exclusion Criteria Pediatric subjects (<12 years of age) with hyperkalaemia with none of following; recipient of an organ transplant, on dialysis, renal artery stenosis, and acute kidney injury or a history of acute renal insufficiency in the past 3 months. Open Enrollment Contact Name: Brandi WellsContact Phone: (904) 244-4693Contact Email: brandi.wells@jax.ufl.edu Investigators Mohammad Ilyas, M.B.B.S. (M.D.) Pediatrics